Idelalisib monotherapy and durable responses in patients with relapsed or refractory Waldenstroms Macroglobulinemia (WM).

• DOI: 10.1200/jco.2015.33.15_suppl.8532
• Publication Date: 2019-04-19T20:30:14Z
• Authors: Steven Coutre; John Leonard; Christopher Flowers; Andrew John Davies; Wojciech Jurczak; John C. Byrd; Stephen Edward Fo...; Sissy Peterman; Leanne Holes; Yoonjin Cho; Bess Sorenson; Wayne Russell God...; Ajay K. Gopal
• Keywords: 03 medical and health sciences; 0302 clinical medicine; 3. Good health

8532 Background: Idelalisib (Zydelig), a selective oral inhibitor of PI3Kδ, demonstrated considerable anti-tumor activity in patients with relapsed/refractory iNHL in phase 1 (p1; Flinn, 2014), and...